3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Papillomavirus Infections
1
Oropharyngeal Neoplasms
1
Melanoma
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Carcinoma, Non-Small-Cell Lung
1
Advanced/Metastatic Solid Tumors
1
Interventions
Carboplatin
25
Etoposide
23
Cisplatin
16
pembrolizumab
9
Topotecan
9
atezolizumab
7
Pemetrexed
7
Nivolumab
7
Radiosurgery
6
Irinotecan
5
durvalumab
4
Paclitaxel
4
Gemcitabine
4
Albumin-Bound Paclitaxel
4
rovalpituzumab tesirine
3
etoposide phosphate
3
Radiotherapy
3
Magnetic Resonance Spectroscopy
3
Ipilimumab
3
Cyclophosphamide
3
vistusertib
2
roniciclib
2
pelcitoclax
2
pazopanib
2
epacadostat
2
amrubicin
2
Vorinostat
2
Radiation
2
Fluorodeoxyglucose F18
2
Doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Small Cell Lung Carcinoma
×
utomilumab
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts